Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanism of Entresto in Heart Failure (Aim 2)
NCT03005184Phase 2Withdrawn
- Sponsor
- Vanderbilt University Medical Center
- Start
- Sep 2017
- Primary completion
- Jan 2020
- Countries
- 1
01
Overview
A Phase 2 trial of sacubitril + valsartan in heart failure with reduced ejection fraction (HFrEF), sponsored by Vanderbilt University Medical Center. Planned start Sep 2017; status: withdrawn.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT03005184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03005184.